<DOC>
	<DOCNO>NCT00673257</DOCNO>
	<brief_summary>RATIONALE : Collecting store sample blood patient cancer study laboratory may help doctor learn patient respond treatment certain chemotherapy drug . PURPOSE : This laboratory study look pharmacokinetics daunorubicin treat young patient cancer .</brief_summary>
	<brief_title>Pharmacokinetics Daunorubicin Treating Young Patients With Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine pharmacokinetics daunorubicin hydrochloride pediatric patient malignancy . Secondary - Evaluate relationship body composition ( percent body fat ) pharmacokinetics daunorubicin hydrochloride patient . - Correlate pharmacokinetics daunorubicin hydrochloride gender , age , ethnic background patient . - Explore , preliminary fashion , possible relationship pharmacokinetic result toxicity . - Explore , preliminary fashion , possible relationship pharmacokinetic result renal hepatic function complete blood count . - Explore , preliminary fashion , possible genetic polymorphism may influence daunorubicin hydrochloride disposition . OUTLINE : This multicenter study . Patients undergo blood collection prior , periodically , treatment daunorubicin hydrochloride pharmacokinetic analysis . Patients also undergo body composition test within 7 day administration daunorubicin hydrochloride use dual-energy x-ray absorptiometry . PROJECTED ACCRUAL : A total 100 patient accrue study .</detailed_description>
	<mesh_term>Daunorubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis malignancy Must receive chemotherapy regimen include daunorubicin hydrochloride administer infusion duration &lt; 24 hour either 1 2day schedule , include bolus short infusion schedule PATIENT CHARACTERISTICS : Not pregnant nursing No significant uncontrolled systemic illness Large implant prosthesis allow ( undergo dual energy xray absorptiometry scan ) PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>unspecified childhood solid tumor , protocol specific</keyword>
</DOC>